ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

VSTM Verastem Inc

3.50
-0.16 (-4.37%)
14 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Verastem Inc VSTM NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.16 -4.37% 3.50 23:00:08
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.67 3.46 3.67 3.47 3.66
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/5/202406:01EDGAR2Form 8-K - Current report
24/5/202406:00BWVerastem Oncology Announces the Initiation of a Rolling..
23/5/202416:24EDGAR2Form 8-K - Current report
23/5/202416:01BWVerastem Oncology Announces Positive Initial Interim Safety..
09/5/202415:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:02BWVerastem Oncology Reports First Quarter 2024 Financial..
07/5/202406:30BWVerastem Oncology to Present at the RBC Capital Markets..
18/4/202415:05BWVerastem Oncology Announces Appointment of John Hayslip,..
04/4/202406:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
18/3/202406:00BWGlobal Patient Survey Results Reveal Significant Negative..
14/3/202415:05BWVerastem Oncology Reports Fourth Quarter and Full Year 2023..
11/3/202416:07EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/3/202406:30BWVerastem Oncology Announces Multiple Oral Presentations at..
05/3/202416:27BWVerastem Oncology Receives Orphan Drug Designation from FDA..
05/3/202415:30BWVerastem Oncology Announces Preclinical Presentations for..
08/2/202415:22EDGAR2Form SC TO-I - Tender offer statement by Issuer
02/2/202408:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/1/202415:01EDGAR2Form 8-K - Current report
29/1/202406:00BWVerastem Oncology Outlines Key 2024 Strategic Priorities and..
19/1/202406:54EDGAR2Form 8-K - Current report
18/1/202415:00BWVerastem Oncology Granted Fast Track Designation for..
11/1/202406:00BWVerastem Oncology to Participate in the B. Riley Securities..
09/1/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:02EDGAR2Form 8-K - Current report
05/1/202406:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
28/12/202315:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:01EDGAR2Form DEF 14A - Other definitive proxy statements
18/12/202306:00BWVerastem Oncology Selects Oral KRAS G12D Inhibitor..
13/12/202306:00BWVerastem Oncology Announces Initiation of a Confirmatory..
08/12/202315:10EDGAR2Form PRE 14A - Other preliminary proxy statements
20/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
13/11/202306:00BWNew Healthcare Professional Component of Let’s Talk About..
08/11/202316:01EDGAR2Form S-3 - Registration statement under Securities Act of..
08/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:12BWVerastem Oncology Reports Third Quarter 2023 Financial..
07/11/202306:00BWFirst-Of-Its-Kind, Multi-National Patient Impact Survey..
06/11/202306:00BWVerastem Oncology Announces Efficacy and Safety Data of..
27/10/202315:41EDGAR2Form 8-K - Current report
26/10/202315:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202315:05BWVerastem Oncology Strengthens Executive Leadership Team with..
18/10/202315:50BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
14/10/202311:30BWVerastem Oncology Announces Initial Results of RAMP 203..
10/10/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202306:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
28/9/202313:27EDGAR2Form 8-K - Current report
28/9/202313:15BWVerastem Presents Avutometinib and Defactinib Combination..
25/9/202315:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

Delayed Upgrade Clock